Sentiment to ACL will not be helped by Bioshares latest update released today. Essentially a very basic dot point summary of the company in 8 lines one of which was; the challenge for HA-irinotecan will be willingness by hospital pharmacies to substitute it for a very cheap existing drug
The concluding comment; In-licensing of new compounds in March does not indicate ACL's confidence of a strong trial result. Recommendation sell.
Update, page-54
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable